Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study

Background: COVID-19 treatment remains a challenge for medicine because of the extremely short time for clinical studies of drug candidates, so the drug repurposing strategy, which implies the use of well-known and safe substances, is a promising approach. Objective: We present the results of an obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Akasov, R. A., Khaydukov, E. V., Andreyuk, D. S., Sholina, N. V., Sheremeta, A. N., Romanov, D. V., Kostyuk, G. P., Panchenko, V. Ya., Kovalchuk, M. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960625/
https://www.ncbi.nlm.nih.gov/pubmed/35359854
http://dx.doi.org/10.3389/fphar.2022.755745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960625/
https://www.ncbi.nlm.nih.gov/pubmed/35359854
http://dx.doi.org/10.3389/fphar.2022.755745

Ejemplares similares